SGO 2023 Conference Coverage on VuMedi
SGO 2023 Phase 3 UP-NEXT Trial: Upifitamab Rilsodotin, a NaPi2b-Directed ADC, in Platinum-Sensitive Recurrent Ovarian Cancer
By
SGO 2023 Conference Coverage on VuMedi
FEATURING
Debra Richardson
By
SGO 2023 Conference Coverage on VuMedi
FEATURING
Debra Richardson
Login to view comments.
Click here to Login
